The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive role of circulating tumor DNA for locally advanced esophageal squamous cell carcinoma before surgery.
 
Ryota Kobayashi
No Relationships to Disclose
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical
 
Kohei Nakamura
No Relationships to Disclose
 
Yuki Hoshi
No Relationships to Disclose
 
Keiso Ho
No Relationships to Disclose
 
Masashi Takeuchi
No Relationships to Disclose
 
Kazumasa Fukuda
No Relationships to Disclose
 
Rieko Nakamura
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Hiroshi Nishihara
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Eisai; Ethicon; Intuitive Surgical; Japan Lifeline Co.,Ltd.; Kaken Pharmaceutical; Kowa; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smart Hospital Inc.; Sysmex; T-PEC CORPORATION; Taiho Pharmaceutical; Takeda; Toray Industries; TSUMURA & CO.
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)